Colorectal cancer screening: foreign guidelines on fecal immunochemical test cut-off (review)
##article.numberofdownloads## 8
##article.numberofviews## 118
pdf (Русский)

Keywords

fecal immunochemical test (FIT)
fecal occult blood test
screening, colon cancer
colorectal cancer
hemoglobin
colonoscopy
review

How to Cite

Andreev, D., Kashurnikov , A., & Zavyalov, A. (2021). Colorectal cancer screening: foreign guidelines on fecal immunochemical test cut-off (review). Voprosy Onkologii, 67(4), 456–462. https://doi.org/10.37469/0507-3758-2021-67-4-456-462

Abstract

Introduction. According to WHO data for 2020, colorectal cancer occupies first (highest) position
(excluding non-melanoma skin cancer) in the top ranking list of the most frequent cancers in the
Russian Federation.  Colorectal cancer screening plays a pivotal role in early diagnosis and treatment. The best positive threshold values for hemoglobin concentration in a quantitative fecal immunochemical test (FIT) are postulated in a fraction of foreign recommendations. We reviewed the FIT cut-off values in those clinical guidelines.

Materials and methods. The relevant publications were retrieved from PubMed and Google. The search horizon covered the last decade. Searches used the terms: «fecal immunochemical test» AND «screening» OR «cancer» AND «colorectal» OR «colon» OR «rectum", as well as other semantic and thematic forms. The recommendations appeared in last decade were reviewed.

Results. This review summarizes the cut-off values for hemoglobin concentration in FIT, included in the clinical and laboratory guidelines developed in such regions as: Europe, Canada, USA, New Zealand. Many CRC screening programs use the FIT with a threshold setting for interpreting a positive test result. In practice, a wide range of options for threshold hemoglobin concentrations is used to interpret positive results of quantitative FIT. The FIT cut-off value is critically important to select the size of population for further examination depending on capacity of colonoscopy units.

Discussion and conclusions. The foreign guidelines don’t establish single unified approach for FIT results interpretation, which would be an optimal fit for all imaginable practical situations in healthcare system. Improvement of screening techniques based on FIT would lead to the further steps on the way towards more effective and safe CRC diagnosis.

https://doi.org/10.37469/0507-3758-2021-67-4-456-462
##article.numberofdownloads## 8
##article.numberofviews## 118
pdf (Русский)

References

van Melle M, Yep Manzano SIS, Wilson H et al. Faecal immunochemical test to triage patients with abdominal symptoms for suspected colorectal cancer in primary care: review of international use and guidelines // Fam Pract. 2020 Oct;37(5):606–15.

World Health Organization. International Agency for Research on Cancer. The Global Cancer Observatory [Internet]. 2021 [cited 2021 Feb 11]. https: // doi: gco.iarc.fr/

Heisser T, Weigl K, Hoffmeister M, Brenner H. Age-specific sequence of colorectal cancer screening options in Germany: A model-based critical evaluation // PLoS Med. 2020 Jul;17(7):e1003194.

Brenner H, Werner S. Selecting a Cut-off for Colorectal Cancer Screening With a Fecal Immunochemical Test // Clin Transl Gastroenterol. 2017 Aug;8(8):e111.

van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population // Gastroenterology. 2008 Jul;135(1):82–90.

Bretagne J-F, Piette C, Cosson M et al. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening // Dig liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2019 Oct;51(10):1461–9.

Tinmouth J, Lansdorp-Vogelaar I, Allison JE. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know // Gut. 2015 Aug;64(8):1327–37.

Argilés G, Tabernero J, Labianca R et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Vol. 31 // Annals of oncology : official journal of the European Society for Medical Oncology. England. 2020:1291–305.

Halloran SP, Launoy G, Zappa M. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Faecal occult blood testing // Endoscopy. 2012 Sep;44 Suppl 3:SE65–87.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Colorectal Cancer Screening. Version 2.2020 — June 8, 2020. [Internet]. [cited 2021 Mar 2]. https: // doi: www.NCCN.org

Lin JS, Piper MA, Perdue LA et al. Screening for Colorectal Cancer: A Systematic Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Jun. (Evidence Syntheses, No. 135.). In 2016. https: // doi: www.ncbi.nlm.nih

Robertson DJ, Lee JK, Boland CR. et al. Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer // Gastroenterology. 2017 Apr;152(5):1217–1237.e3.

Recommendations on screening for colorectal cancer in primary care // C Can Med Assoc J=J l’Association medicale Can. 2016 Mar;188(5):340–8.

Cancer Society of New Zealand (2019). Bowel (colorectal) screening position statement. Wellington: NZCS [Internet]. [cited 2021 Mar 3]. https: // doi: cancernz.org.nz/assets/Positions-Statements/Cancer-Society-Position-Statement-Template-FA-amend1.pdf

NICE. Suspected cancer: recognition and referral. NICE guideline [NG12] [Internet]. 2021 [cited 2021 Mar 4]. https: // doi: www.nice.org.uk/guidance/ng12/chapter/1-Recommendations-organised-by-site-of-cancer#lower-gastrointestinal-tract-cancers

NICE. Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care. [Internet]. 2020 [cited 2021 Mar 4]. https: // doi: www.nice.org.uk/guidance/dg30

Rijksinstituut voor Volksgezondheid en Milieu. Ministerie van Volksgezondheid, Welzijn en Sport. Hoe gaat het bevolkingsonderzoek darmkanker? Publicatie datum: 11-01-2021. [Internet]. Nederland; [cited 2021 Mar 12]. https: // doi: www.rovid.nl/rivm/aco/2021/rivm-aco-20210111-idc4ltbxl-web-hd.mp4

Rijksinstituut voor Volksgezondheid en Milieu. Ministerie van Volksgezondheid, Welzijn en Sport. Gebruiksaanwijzing ontlastingstest bevolkingsonderzoek darmkanker. Wijzigingsdatum 04-03-2020. [Internet]. 2021 [cited 2021 Mar 12]. https: // doi: www.rovid.nl/rivm/aco/2018/rivm-aco-20180809-idde82why-web-hd.mp4

Gezondheidsraad. Afkapwaarde in bevolkingsonderzoek darmkanker. Den Haag: Gezondheidsraad, 2019; publicatienr. 2019/13. [Internet]. [cited 2021 Mar 12]. https: // doi: www.gezondheidsraad.nl

Bénard F, Barkun AN, Martel M, von Renteln D. Systematic review of colorectal cancer screening guidelines for average-risk adults: Summarizing the current global recommendations // World J Gastroenterol. 2018 Jan;24(1):124–38.

Abeloff’s clinical oncology, sixth edition. Niederhuber J.E., Armitage J.O., Kastan M.B., Doroshow J.H., Tepper J.E. Editors, 2020; Copyright © 2020 by Elsevier.

Selby K, Levine EH, Doan C, Gies A, Brenner H, Quesenberry C, Lee JK, Corley DA. Effect of Sex, Age, and Positivity Threshold on Fecal Immunochemical Test Accuracy: A Systematic Review and Meta-analysis // Gastroenterology. 2019 Dec;157(6):1494–505.

Georgiou Delisle T, D’Souza N, Chen M. et al. Can FIT rule out colorectal cancer in symptomatic patients? Diagnostic test accuracy results from 9,822 patients in the NICE FIT study // J Clin Oncol [Internet]. 2020;38(15_suppl):4093. https: // doi: org/10.1200/JCO.2020.38.15_suppl.4093

Rijksinstituut voor Volksgezondheid en Milieu. Ministerie van Volksgezondheid, Welzijn en Sport. Bevolkingsonderzoek darmkanker: professionals. [Internet]. 2021 [cited 2021 Mar 12]. https: // doi: www.rivm.nl/bevolkingsonderzoek-darmkanker/professionals

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2021